Design, synthesis, and evaluation of indeno[2,1-c]pyrazolones for use as inhibitors against hypoxia-inducible factor (HIF)-1 transcriptional activity.

[1]  Shinichiro Fuse,et al.  Synthesis of Pyrazolofuropyrazine via One-Pot SNAr Reaction and Intramolecular Direct C–H Arylation , 2018, Synthesis.

[2]  S. Påhlman,et al.  Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.

[3]  M. Won,et al.  Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015) , 2016, Expert opinion on therapeutic patents.

[4]  So Yeon Kim,et al.  Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications , 2015, Molecules.

[5]  H. Osada,et al.  Methyl 3-((6-methoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)amino)benzoate (GN39482) as a tubulin polymerization inhibitor identified by MorphoBase and ChemProteoBase profiling methods. , 2015, Journal of medicinal chemistry.

[6]  R. Haggam.  Cu(I)-catalyzed intramolecular cyclizations of substituted 2-iodobenzophenones under thermal and microwave conditions , 2013 .

[7]  He-sheng Huang,et al.  Recent agents targeting HIF‐1α for cancer therapy , 2013, Journal of cellular biochemistry.

[8]  H. Ban,et al.  Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors. , 2013, ACS medicinal chemistry letters.

[9]  Hu Li,et al.  Synthesis of fluorenone derivatives through Pd-catalyzed dehydrogenative cyclization. , 2012, Organic letters.

[10]  S. Batra,et al.  Synthesis of substituted pyrazolo[4,3-b]pyridines via copper-mediated intramolecular C–N cross-coupling of primary allylamines , 2012 .

[11]  Kyeong Lee,et al.  Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. , 2012, European journal of medicinal chemistry.

[12]  Y. Uto,et al.  Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 – 2010) , 2011, Expert opinion on therapeutic patents.

[13]  H. Ban,et al.  Identification of HSP60 as a primary target of o-carboranylphenoxyacetanilide, an HIF-1alpha inhibitor. , 2010, Journal of the American Chemical Society.

[14]  H. Ban,et al.  Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[15]  G. Melillo,et al.  Development of HIF-1 inhibitors for cancer therapy , 2009, Journal of cellular and molecular medicine.

[16]  P. Knochel,et al.  Preparation of polyfunctional arylmagnesium, arylzinc, and benzylic zinc reagents by using magnesium in the presence of LiCl. , 2009, Chemistry.

[17]  H. Ban,et al.  1-[4-(N-Benzylamino)phenyl]-3-phenylurea derivatives as a new class of hypoxia-inducible factor-1alpha inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[18]  G. Semenza,et al.  Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer , 2009, Clinical Cancer Research.

[19]  Dong-Hoon Shin,et al.  A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1α , 2008, Molecular Cancer Therapeutics.

[20]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[21]  C. Bolm,et al.  Ligand-Free Copper-Catalyzed N-Arylation of Nitrogen Nucleophiles , 2007 .

[22]  Philip J. Merta,et al.  Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[23]  Philip J. Merta,et al.  Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability. , 2007, Bioorganic & medicinal chemistry letters.

[24]  G. Melillo.  Targeting hypoxia cell signaling for cancer therapy , 2007, Cancer and Metastasis Reviews.

[25]  Jong-Wan Park,et al.  Versatile pharmacological actions of YC-1: anti-platelet to anticancer. , 2004, Cancer letters.

[26]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[27]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[28]  Karen A. Rossi,et al.  Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern. , 2002, Journal of medicinal chemistry.

[29]  H. Dyson,et al.  Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Livingston,et al.  Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[32]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[33]  P. Ratcliffe,et al.  Independent function of two destruction domains in hypoxia‐inducible factor‐α chains activated by prolyl hydroxylation , 2001, The EMBO journal.

[34]  S. White,et al.  HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[36]  G. B. Jones,et al.  Annulation strategies for benzo[b]fluorene synthesis: efficient routes to the kinafluorenone and WS-5995 antibiotics. , 2000, The Journal of organic chemistry.

[37]  R. Conaway,et al.  Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Eamonn R. Maher,et al.  Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.

[39]  L. Poellinger,et al.  Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.

[40]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[41]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[42]  G. Semenza,et al.  Transactivation and Inhibitory Domains of Hypoxia-inducible Factor 1α , 1997, The Journal of Biological Chemistry.

[43]  M. Nagao,et al.  Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit* , 1997, The Journal of Biological Chemistry.

[44]  G. Semenza,et al.  Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[45]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[46]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Kende,et al.  NOVEL AG(I)-CATALYSIS OF AN INTRAMOLECULAR 1,3-DIPOLAR CYCLOADDITION , 1995 .

[48]  R. Huisgen,et al.  1,3‐Dipolare Cycloadditionen, 90. Diphenylnitrilimin und substituierte Butadiene; Substituenteneffekte und Geschwindigkeit der Cycloaddition , 1983 .

[49]  D. A. Shirley,et al.  The Metalation of 1-Phenyl- and 1-Methylpyrazole with n-Butyllithium , 1958 .

[50]  T. Hirokawa,et al.  Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. , 2008, Bioorganic & medicinal chemistry letters.

[51]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[52]  G. Semenza,et al.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001, Genes & development.